Rockefeller Capital Management L.P. increased its stake in shares of Elanco Animal Health (NYSE:ELAN) by 6.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 8,443 shares of the company’s stock after purchasing an additional 486 shares during the period. Rockefeller Capital Management L.P.’s holdings in Elanco Animal Health were worth $249,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Andra AP fonden raised its stake in shares of Elanco Animal Health by 17.9% in the 3rd quarter. Andra AP fonden now owns 131,500 shares of the company’s stock valued at $3,497,000 after purchasing an additional 20,000 shares in the last quarter. State Street Corp boosted its position in Elanco Animal Health by 46.3% during the 3rd quarter. State Street Corp now owns 9,763,351 shares of the company’s stock valued at $259,608,000 after purchasing an additional 3,087,565 shares during the period. Stifel Financial Corp increased its position in Elanco Animal Health by 12.7% in the third quarter. Stifel Financial Corp now owns 190,280 shares of the company’s stock worth $5,037,000 after buying an additional 21,438 shares during the period. Artemis Investment Management LLP acquired a new stake in Elanco Animal Health in the fourth quarter worth $8,844,000. Finally, 1ST Source Bank bought a new stake in Elanco Animal Health in the fourth quarter valued at $1,435,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Elanco Animal Health stock traded down $0.91 during trading on Friday, hitting $27.22. The stock had a trading volume of 498,058 shares, compared to its average volume of 4,578,115. The business has a fifty day moving average of $30.65 and a two-hundred day moving average of $28.26. Elanco Animal Health has a fifty-two week low of $25.25 and a fifty-two week high of $35.46. The firm has a market cap of $10.73 billion, a P/E ratio of 141.17, a PEG ratio of 1.91 and a beta of 0.73. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.12 and a quick ratio of 1.67.
Several research analysts have commented on the stock. Morgan Stanley upgraded shares of Elanco Animal Health from an “equal” rating to an “equal weight” rating and decreased their target price for the stock from $34.00 to $32.00 in a research report on Thursday, November 7th. Gabelli reaffirmed a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, January 14th. TheStreet upgraded Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Tuesday, December 24th. UBS Group decreased their price target on Elanco Animal Health from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Finally, Raymond James began coverage on shares of Elanco Animal Health in a research note on Thursday, January 9th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. Elanco Animal Health has an average rating of “Hold” and an average target price of $33.83.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.